Ching-Shih Chen, PhD

Lucius A. Wing Chair
of Cancer Research & Therapy,
Kimberly Professor,
Professor of Medicinal Chemistry,
Internal Medicine, and Urology

336 Parks Hall
500 West 12th Avenue
Columbus, OH 43210

E-mail: chen.844@osu.edu
Phone: (614) 688-4008

Medicinal Chemistry / Faculty and Research / Ching-Shih Chen

Education

Postdoctoral Research 1986, University of Wisconsin, Madison, WI.
Ph.D. 1985, University of Wisconsin, Madison, WI.
M.S. 1980, National Taiwan University.
B.S. 1978, National Taiwan University.

Areas of Interest

Dr. Chen¹s research focuses on exploring signaling pathways that govern cancer cell survival as targets for drug discovery and design. He employs a multidisciplinary approach to identify new molecular targets by combining expertise ranging from synthetic organic chemistry to molecular and cellular
biology in his research team. His laboratory has designed a series of novel small-molecule agents that cause apoptosis by attacking different molecular defects in tumor cells. These molecular targets include Akt signaling, Bcl-xL/Bcl-2, histone deacetylase, DNA methyltransferase, cyclin D1, b-catenin, and androgen receptor. These novel agents mediate antiproliferative effects through mechanisms distinct from that of conventional chemotherapeutic regimens, which will provide a rational approach for molecular targeted cancer therapy. Currently, many of these promising compounds are undergoing in vivo target validation in his laboratory using a number of cancer models including prostate, breast, lung, liver, and ovarian cancers. Two of these agents, the PDK-1 inhibitor OSU-03012 and the histone deacetylase inhibitor HDAC-42, are currently undergoing preclinical testing under the Rapid Access to Intervention Development (RAID) program at the National Cancer Institute, which will facilitate the translation of these agents into the clinic.

These studies are supported by research grants by the National Institutes of Health, Susan Komen Foundation, The Leukemia and Lymphoma Society, and Army Prostate Cancer Research Program.

[ View Recent Publications ]

Courses Taught

Biopharmacy 602: The second in a two-course sequence which provides the fundamental background in modern molecular life science required for pharmacy studies.

Honors & Awards (in the past three years)

2005 The Lucius A. Wing Chair of Cancer Research and Therapy, OSU
Comprehensive Cancer Center

2005 Advisory Board Committee, Institute of Biological Chemistry, Academia
Sinica, Taiwan

2004 Winner of the V Foundation-AACR Grants in Translational Cancer Research

2004 Elected Fellow, American Association for the Advancement of Science
(AAAS)

2003 Kimberly Chair Professorship, OSU College of Pharmacy

Professional Experience

2002-present: Professor of Internal Medicine and Urology, College of Medicine,
The Ohio State University.

2001-present: Member, James Comprehensive Cancer Center, The Ohio State University.

2001-present: Professor of Medicinal Chemistry, Division of Medicinal Chemistry & Pharmacognosy, College of Pharmacy, The Ohio State University.

1998-2001: Professor of Pharmaceutical Sciences, University of Kentucky.

1995-2001: Member, Markey Cancer Center, University of Kentucky.

1995-1998: Associate Professor of Pharmaceutical Sciences, University of Kentucky.

1991-1995: Associate Professor of Medicinal Chemistry & Pharmacognosy,
University of Rhode Island.

1987-1991: Assistant Professor of Medicinal Chemistry & Pharmacognosy,
University of Rhode Island.